跳至主要内容
临床试验/TCTR20230320008
TCTR20230320008已完成不适用

iver injury in mild COVID-19 with various COVID pandemic phases, a real-world study.

avamindradhiraj University Research Fund0 个研究点目标入组 300 人开始时间: 2023年3月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
300

研究概览

简要总结

We report more than a third of the cases are associated with mild liver injuries. Even liver-specific of ALT, our report a greater AST than ALT.Several patients with liver damage had modest baseline transaminitis; nevertheless, this was not a barrier to initiating medication.Only four (14.8%) of the previous liver disease had baseline compensated cirrhosis, and none had significant transaminitis.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • Eligible individuals were inpatients age >18 years, who were admitted to the hospitel, hospital field, and cohort ward after RT-PCR testing confirmed the diagnosis of COVID-19 infection. For hospitel and hospital fields, symptomatic COVID-19 without pneumonia, and absence of risk factors for severe disease are inclusion criteria. Any of the following cohort wards qualify for symptomatic COVID-19 treatment: having severe illness risk factors or with mild pneumonia.

排除标准

  • 1.Patients with pneumonia and hypoxia will require an oxygen supplement
  • 2.Patients with moderate to severe pneumonia (infiltration > 20% of total lung)
  • 3.Pregnant or breast- feeding women.

研究者

发起方
avamindradhiraj University Research Fund

相似试验